Table 1. Demographic and clinical characteristics of subjects for treatment groups.
| n | Thalidomide Group | n | Placebo Group | |
|---|---|---|---|---|
| Age | 17 | 73.6 (8.22) | 8 | 73.6 (4.84) |
| Education | 17 | 14.1 (2.30) | 6 | 13.3 (1.97) |
| Visit 1 MMSE | 17 | 21.8 (2.46) | 7 | 22.0 (5.26) |
| Baseline ADAS-cog | 17 | 22.7 (7.81) | 7 | 26.9 (18.7) |
| Baseline CDR-sb | 17 | 5.12 (2.50) | 8 | 7.38 (5.36) |
| Baseline ADCS-ADL | 17 | 57.8 (9.34) | 8 | 51.0 (17.9) |
| Baseline NPI | 17 | 9.71 (12.1) | 8 | 18.4 (22.1) |
| Visit 7 MMSE | 5 | 19.2 (4.44) | 5 | 19.6 (7.30) |
| EOS ADAS-cog | 14 | 24.1 (10.1) | 6 | 28.9 (20.6) |
| Visit 10 MMSE | 10 | 19.0 (3.83) | 6 | 19.5 (9.81) |
| EOS CDR-sb | 14 | 6.82 (2.49) | 7 | 9.21 (6.22) |
| EOS ADCS-ADL | 14 | 52.4 (10.9) | 7 | 46.6 (19.0) |
| EOS NPI | 14 | 14.3 (14.0) | 7 | 14.0 (23.2) |
Abbreviations: ADAS-cog= Alzheimer's Disease Assessment Scale-cognitive, ADCS-ADL=Alzheimer's Disease Cooperative Study Activities of Daily Living Scale; CDR-sb=Clinical Dementia Rating-sum of boxes; MMSE=Mini-Mental State Examination; NPI=Neuropsychiatric Inventory; EOS = End of Study. Values are Mean (SD)